| 000 | 01111 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250513061340.0 | ||
| 264 | 0 | _c19930809 | |
| 008 | 199308s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/0140-6736(93)92328-q _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGoudemand, M | |
| 245 | 0 | 0 |
_aSpecific anti-HAV immunoglobulin. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cJul 1993 |
||
| 300 |
_a239 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comment; Controlled Clinical Trial; Letter | ||
| 650 | 0 | 4 | _aAntibody Specificity |
| 650 | 0 | 4 |
_aHepatitis A _xprevention & control |
| 650 | 0 | 4 | _aHepatitis A Antibodies |
| 650 | 0 | 4 |
_aHepatitis Antibodies _ximmunology |
| 650 | 0 | 4 |
_aHepatovirus _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunization, Passive |
| 650 | 0 | 4 |
_aImmunoglobulins _ximmunology |
| 700 | 1 | _aManiez-Montreuil, M | |
| 700 | 1 | _aDupressoir-Burlet, M V | |
| 773 | 0 |
_tLancet (London, England) _gvol. 342 _gno. 8865 _gp. 239 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0140-6736(93)92328-q _zAvailable from publisher's website |
| 999 |
_c8100281 _d8100281 |
||